Ironwood Pharmaceuticals, Inc.
Symbol: IRWD
NASDAQ
6.74
USDMarktpreis heute
-1.0492
P/E-Verhältnis
0.1032
PEG-Verhältnis
1.07B
MRK Kapital
- 0.00%
DIV Rendite
Ironwood Pharmaceuticals, Inc. (IRWD) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 92.2 | 656.2 | 620.1 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 0 | 129.1 | 115.5 | 114 | |||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 1.3 | 1.3 | |||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 12 | 7.7 | 9.8 | |||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 233.3 | 780.6 | 745.2 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 18.2 | 20.3 | 22.9 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 3.7 | 0 | 0 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 3.7 | -15.1 | -24.5 | |||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 15.1 | 24.5 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 212.3 | 283.7 | 333.3 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 3.6 | 15.9 | 25.5 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 237.8 | 319.9 | 381.7 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 0 | 471.1 | 1100.5 | 1126.9 | |||||||||||||||||
balance-sheet.row.account-payables | 0 | 7.8 | 0.5 | 0.9 | |||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 202.7 | 3.1 | 120 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 1.2 | 0.7 | 0.2 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 498.3 | 412.9 | 355.8 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 64.3 | 22 | 1.3 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 541.3 | 422.6 | 359.3 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 14.5 | 19.7 | 21.6 | |||||||||||||||||
balance-sheet.row.total-liab | 0 | 817.4 | 448.1 | 521 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0 | 0.2 | 0.2 | 0.2 | |||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -1698.6 | -696.4 | -937.6 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -3 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1355.2 | 1348.6 | 1543.4 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | -346.3 | 652.4 | 605.9 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 471.1 | 1100.5 | 1126.9 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | 0 | -346.3 | 652.4 | 605.9 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||||
Total Investments | 0 | 0 | 15.1 | 24.5 | |||||||||||||||||
balance-sheet.row.total-debt | 0 | 715.5 | 415.9 | 475.8 | |||||||||||||||||
balance-sheet.row.net-debt | 0 | 623.4 | -240.3 | -144.3 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -1002.2 | 175.1 | 528.4 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 1.6 | 1.4 | 1.5 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 72.6 | 65.7 | -333.3 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 32 | 27 | 22.3 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 11.3 | 2.8 | 17.7 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | 0.9 | 8 | 7.7 | |||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.account-payables | 0 | 12.4 | -8.1 | -2.6 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -2 | 2.9 | 12.7 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 1068.2 | 1.7 | 25.2 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -0.3 | -0.1 | -0.3 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -1026 | 0 | 0 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -1026.3 | -0.1 | -0.3 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | -300 | -120.7 | 0 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 6.4 | 9.5 | 19.6 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -126.4 | -24.1 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -111.2 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 570.8 | 111.2 | -4.5 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 277.2 | -237.6 | -4.5 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -0.1 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -565.3 | 36.1 | 257.1 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 92.2 | 657.9 | 621.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 657.5 | 621.9 | 364.8 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 183.4 | 273.8 | 261.9 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -0.3 | -0.1 | -0.3 | |||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 183.2 | 273.6 | 261.6 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 442.7 | 410.6 | 413.8 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 1.6 | 1.4 | 1.5 | |||||||||||||||||
income-statement-row.row.gross-profit | 0 | 441.2 | 409.2 | 412.2 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 232.1 | 160.3 | 181.5 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 233.7 | 160.3 | 181.5 | |||||||||||||||||
income-statement-row.row.interest-income | 0 | 19 | 9.5 | 0.7 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 21.6 | 7.6 | 31.1 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -1157.1 | 2.1 | -31.6 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -1157.1 | 2.1 | -31.6 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 21.6 | 7.6 | 31.1 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1.6 | 9.5 | 0.7 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 0 | 209 | 250.3 | 232.3 | |||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -948.1 | 252.4 | 200.7 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 83.5 | 77.4 | -327.8 | |||||||||||||||||
income-statement-row.row.net-income | 0 | -1002.2 | 175.1 | 528.4 |
Häufig gestellte Frage
Wie hoch ist die Ironwood Pharmaceuticals, Inc. (IRWD) Gesamtvermögen?
Ironwood Pharmaceuticals, Inc. (IRWD) Gesamtvermögen ist 471073000.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist N/A.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.996.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist 1.174.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist -2.264.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist -2.120.
Was ist der Ironwood Pharmaceuticals, Inc. (IRWD) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist -1002239000.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 715538000.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 232124000.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 0.000.